PRELP has been shown to affect the immunogenicity of tumors by upregulating MHC class I surface expression and activating IFN signaling, which could modulate tumor development as well as the TME leading to an enhanced CD8+ T cell infiltration. This evidence concerns the gene PRELP and neoplasm.